☆ 4.5 Editorial Material

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Get Full Text
Add to Collection

Journal

EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 31, Issue 6, Pages 495-498

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2022.2042252

Keywords

Breast cancer; triple negative breast cancer; combinations; antibody drug conjugate; sacituzumab govitecan; ladiratuzumab vedotin

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.